CytRx Files Report With The FDA In Response To The Partial Clinical Hold On Its Phase 2b Arimoclomol ALS Trial

July 2 2009

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, has filed a report with the U.S. Food and Drug Administrations (FDA) in response to the Agency's partial clinical hold on the Company's Phase 2b efficacy clinical trial with its molecular chaperone regulator drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

  • Donate

  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...
  • Register Now!

  • Events

  • Register Now!

  • Cure CMD Channel
    Friends of Cure CMD

  • Navigation

    Show Sub-Pages | Hide Sub-Pages